Physician profile
Erin Warren
NPI 1699122382
$2,568.35
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $67.41 · 2021: $587 · 2022: $894 · 2023: $998 · 2024: $22.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,020.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,019.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $408.06 | 2021-2023 | Jardiance, Mounjaro, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $364.57 | 2021-2023 | Tradjenta, Jardiance, Stiolto Respimat |
| Abbvie INC. | $248.39 | 2021-2023 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $247.77 | 2021-2023 | Wegovy, Rybelsus, Ozempic |
| E.R. Squibb & Sons, L.L.C. | $134.00 | 2022-2023 | Eliquis |
| Glaxosmithkline, LLC. | $133.92 | 2021-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $133.54 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $126.57 | 2021-2024 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $104.13 | 2021-2023 | Farxiga |
| Kowa Pharmaceuticals America, INC. | $96.55 | 2021-2022 | |
| Amgen INC. | $80.38 | 2022-2023 | Evenity, Prolia |
| Exact Sciences Corporation | $75.18 | 2023 | Cologuard Collection Kit |
| Astellas Pharma US INC | $71.52 | 2021-2023 | Myrbetriq, Veozah |
| Avinger INC. | $67.41 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $40.22 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acclarent, INC | $32.08 | 2023 | Relieva Spinplus |
| Janssen Pharmaceuticals, INC | $30.96 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $30.87 | 2021 | |
| Dexcom, INC. | $29.93 | 2023 | Dexcom G6 Transmitter |
| Medicomp INC | $22.00 | 2022 | |
| Embecta Corp. | $21.63 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Bayer Healthcare Pharmaceuticals INC. | $19.71 | 2022 | |
| Corium, LLC | $19.69 | 2022 | |
| Bardy Diagnostics, INC. | $15.37 | 2021 | |
| Seqirus USA INC | $13.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Warren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.